6th International Young Scientist Congress (IYSC-2020) will be Postponed to 8th and 9th May 2021 Due to COVID-19. 10th International Science Congress (ISC-2020).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Study of Adverse Effects of Vildagliptin and Insulin Treatment in Diabetes Mellitus Patients

Author Affiliations

  • 1Research and Development Centre, Bharathiar University, Coimbatore – 641046, INDIA
  • 2Department of Biomedical Engineering, SriSiva Subramaniya Nadar College of Engineering, Kalavakkam, Chennai -603110, INDIA

Res. J. Recent Sci., Volume 3, Issue (ISC-2013), Pages 403-407, (2014)

Abstract

The defective response of the body tissues to insulin leads to Diabetic condition in human beings. The central nervous system which controls the entire motor unit, suffers degeneration that leads to many complications, of which Diabetes Mellitus disease lies most widespread in India. Present-day medicine such as insulin injection and vildagliptin (Dipeptidyl peptidase-4 inhibitor) treatment are associated with serious neuromuscular side effects and nervous impairment. Within this context, aim of our research was to evaluate, by analysing the myocardial dysfunction complexity, the adverse effects induced by vildagliptin in combination with other antidiabetic treatment. Blood glucose level, glycosylated hemoglobin, serum insulin, systolic and diastolic blood pressure, heart rate, myocardial enzymes such as LDH, CK-MB, AST and ECG signals were measured before and after the insulin and vildagliptin treatment in patients. All the above mentioned parameters were altered significantly after the treatment with insulin and vildagliptin. This study may provide evidence to the medical society about the cardiac dysfunction complexity caused by autonomic failure of hypoglycemic actions upon combination therapy of insulin with vildagliptin in diabetes mellitus.

References

  1. Schweizer A., Dejager S., Foley J.E. and Kothny W., Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies, Vasc Health Risk Manag.,7, 49–57(2011)
  2. Brierley E.J., Broughton D.L., James O.F., Alberti K.G., Reduced awareness of hypoglycaemia in the elderly despite an intact counter-regulatory response, QJM, 88, 439–44(1995)
  3. Gawlowski T., Stratmann B., Stork I., Engelbrecht B., Brodehl A., Niehaus K., Körfer R., Tschoepe D. and Milting H., Heat shock protein 27 modification is increased in the human diabetic failing heart, Horm Metab Res., 41, 594–599(2009)
  4. Burgess M.L., McCrea J.C. and Hedrick H.L., Age-associated changes in cardiac matrix and integrins,Mech Ageing Dev.,122, 1739–1756(2001)
  5. Mariappan N., Elks C.M., Sriramula S., Guggilam A., Liu Z., Borkhsenious O. and Francis J. NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes, Cardiovasc Res.,85, 473–483 (2010)
  6. Russell N.E., Higgins M.F., Amaruso M., Foley M., McAuliffe F.M., Troponin T. and pro-B-type natriuretic Peptide in fetuses of type 1 diabetic mothers, Diabetes Care., 32, 2050–2055 (2009)
  7. Feng B., Chen S., George B., Feng Q. and Chakrabarti S., miR133a regulates cardiomyocyte hypertrophy in diabetes, Diabetes Metab Res Rev., 26, 40–49(2010)
  8. Horsdal H.T., Søndergaard F., Johnsen S.P. and Rungby J., Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study, Pharmacoepidemiol Drug Saf., 20, 331–337 (2011)
  9. Corley B.T., Davenport C., Delaney L., Hatunic M. and Smith D., Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse, Diabet Med., 28, 876–879(2011)
  10. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., Woodward M., Ninomiya T., Neal B., MacMahon S. et al. Severe hypoglycemia and risks of vascular events and death, N Engl J Med., 363, 1410–1418 (2010)
  11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet., 352, 837–853(1998)
  12. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., Wright A.D., Turner R.C., Holman R.R., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405–412(2000)
  13. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials, N Engl J Med., 358, 2630–2633 (2008)
  14. Fadini G.P., Boscaro E. and Albiero M., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor1alpha, Diabetes Care.,33, 1607–1609(2010)
  15. Schweizer A., Dejager S., Foley J.E., Couturier A., Ligueros-Saylan M. and Kothny W., Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population, Diabetes Obes Metab.,12, 485–494 (2010)
  16. Betteridge D.J. and Verges B., Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes, Int J Obes Relat Metab Disord., 12, 2477–2481(2005)
  17. Van Poppel P.C., Netea M.G., Smits P. and Tack C.J., Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes, Diabetes Care., 12, 2072–2077 (2011)
  18. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure, J Card Fail.,12, 694–9 (2006)
  19. Ireland R.H., Robinson R.T.C.E., Heller S.R., Marques J.L.B. and Harris N.D., Measurement of high resolution ECG QT interval during controlled hypoglycaemia, Physiol Meas., 21, 295–303 (2000)
  20. Johansen O.E., Neubacher D., von Eynatten M., Patel S. and Woerle H.J., Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme, Cardiovasc Diabetol., 11, (2012)
  21. Horsdal H.T., Søndergaard F., Johnsen S.P. and Rungby J., Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study, Pharmacoepidemiol Drug Saf., 20, 331–337 (2011)